Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MONO-LINYAH vs DEMULEN 1/50-28
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.
Moderate to severe plaque psoriasis,Psoriatic arthritis,Ankylosing spondylitis,Non-radiographic axial spondyloarthritis
FDA: Prevention of pregnancy,Off-label: Treatment of acne vulgaris, dysmenorrhea, endometriosis-related pain, menstrual irregularity
10 mg orally once daily
One tablet orally once daily for 28 consecutive days per cycle.
Terminal elimination half-life is 3–5 hours in adults; prolonged to 8–15 hours in renal impairment (Cr Cl <30 m L/min) and in neonates.
Ethinylestradiol: terminal elimination half-life ~13-27 hours (mean ~17 hours); ethynodiol diacetate (as norethindrone): terminal elimination half-life ~8-11 hours; clinical context: achieved steady-state within 5-10 days; accumulation not significant due to dose interval.
Metabolized via general protein degradation pathways; not primarily metabolized by CYP450 enzymes.
Ethinyl estradiol: CYP3A4; undergoes first-pass metabolism with sulfation and glucuronidation. Ethynodiol diacetate: Deacetylated to norethynodrel, then extensively metabolized via reduction and conjugation.
Predominantly renal as unchanged drug (≥90%); minor biliary/fecal (<5%).
Ethinylestradiol and ethynodiol diacetate are extensively metabolized; urinary excretion accounts for ~40% of ethinylestradiol metabolites and ~50-60% of ethynodiol diacetate metabolites; fecal excretion accounts for ~30% of ethinylestradiol metabolites and ~35% of ethynodiol diacetate metabolites; biliary excretion contributes to enterohepatic circulation.
20–30% bound to albumin.
Ethinylestradiol: >97% bound, primarily to albumin, with ~2% bound to sex hormone-binding globulin (SHBG); ethynodiol diacetate (as norethindrone): ~95% bound, primarily to albumin and SHBG.
0.5–0.8 L/kg, consistent with distribution into total body water; increased in edema or ascites.
Ethinylestradiol: Vd ~2-4 L/kg; distributes extensively into body tissues; ethynodiol diacetate (as norethindrone): Vd ~4 L/kg; indicates wide distribution including reproductive tissues.
Oral bioavailability is 60–70% (first-pass metabolism ~30–40%); immediate-release tablets.
Oral: ethinylestradiol bioavailability ~40-60% due to first-pass metabolism; ethynodiol diacetate bioavailability ~60-80% after oral administration.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 5 mg once daily; GFR <15 m L/min: not recommended
No dosage adjustment required for renal impairment. Use is not recommended in patients with severe renal impairment due to potential adverse effects.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended
Contraindicated in patients with Child-Pugh C cirrhosis. For Child-Pugh A or B, use is generally not recommended; if used, monitor closely for adverse effects.
Weight <20 kg: 2.5 mg once daily; 20-40 kg: 5 mg once daily; >40 kg: 10 mg once daily
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 28 days per cycle.
Start at 5 mg once daily; titrate based on response and tolerability
Not indicated for use in postmenopausal women. No specific dose adjustment recommended for elderly, but consider increased risk of thromboembolic disorders.
None
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, stroke, thromboembolism). Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Increased risk of infections,Hypersensitivity reactions,Hepatotoxicity,Inflammatory bowel disease exacerbation
Thromboembolic disorders (DVT, PE, stroke, MI),Hepatic neoplasia (benign/malignant liver tumors),Increased risk of gallbladder disease,Hypertension,Carbohydrate/lipid metabolic effects,Ocular disturbances (retinal thrombosis, optic neuritis),Depression,Fetal harm if used during pregnancy
Hypersensitivity to active substance or excipients,Clinically significant active infection
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically meaningful. Avoid excessive alcohol as it may impair liver function.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinical significance is unclear. Maintain consistent intake of vitamin C-rich foods as they may increase estrogen absorption. Avoid St. John's wort, which reduces contraceptive efficacy.
Pregnancy Category X. First trimester: High risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: Risk of oligohydramnios, fetal renal impairment, and neonatal anuria. Contraindicated in all trimesters.
Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimesters: association with masculinization of female fetus, adrenal suppression, and possible long-term metabolic effects. Estrogen component may increase risk of VACTERL anomalies.
Excreted in human milk. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., renal toxicity), breast-feeding is contraindicated during therapy and for at least 30 days after last dose.
Contraindicated during breastfeeding. Estrogens reduce milk production and quality. M/P ratio not established; ethinyl estradiol and norgestrel are excreted in breast milk in small amounts, potentially causing adverse effects in the infant.
Not applicable; contraindicated in pregnancy. If inadvertent exposure, immediate discontinuation is required; no dose adjustment is recommended as alternative therapy should be initiated.
No adjustments; absolute contraindication in pregnancy. Drug should be discontinued immediately upon pregnancy diagnosis. No established safe dose in pregnancy.
Mono-Linyah (ethinyl estradiol and norgestimate) is a combined oral contraceptive. Counsel patients about the increased risk of venous thromboembolism (VTE), especially in smokers over 35. Missed pill instructions vary by how many are missed. Consider drug interactions with rifampin, certain anticonvulsants (e.g., carbamazepine, phenytoin), and St. John's Wort, which may reduce efficacy. Use with caution in patients with a history of migraine with aura, as it may increase stroke risk.
Demulen 1/50-28 is a monophasic combined oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Due to the 50 mcg estrogen dose, it carries an increased risk of venous thromboembolism compared to lower-dose pills; avoid in patients with migraine with aura, hypertension >160/100 mm Hg, or age >35 who smoke. The 28-day pack includes 21 active pills and 7 placebo pills; breakthrough bleeding is more common with higher estrogen. Caution with hepatic enzyme inducers like rifampin or anticonvulsants may reduce efficacy.
Take one pill daily at the same time each day to maintain effective hormone levels.,If you miss a pill, follow the package insert instructions or consult your healthcare provider.,Use a backup contraceptive method (e.g., condoms) if you miss pills or if you have vomiting or severe diarrhea.,This medication does not protect against HIV or other sexually transmitted infections.,Smoking while using this pill increases your risk of serious cardiovascular events; do not smoke.,Contact your healthcare provider if you experience leg pain/swelling, chest pain, shortness of breath, or severe headache.
Take one pill daily at the same time, preferably with food to reduce nausea.,The first 7 days of the first cycle require a backup contraceptive method if not starting on day 1 of menses.,Missed pill: if one active pill is missed, take it as soon as remembered and continue; if two or more active pills are missed, take the last missed pill, skip the others, use backup for 7 days, and consider emergency contraception.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.,Report symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or severe headache.,The 7 placebo pills are for withdrawal bleeding; start next pack on time regardless of bleeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MONO-LINYAH vs DEMULEN 1/50-28, answered by our medical review team.
MONO-LINYAH is a Combination Oral Contraceptive that works by Monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.. DEMULEN 1/50-28 is a Combination Oral Contraceptive that works by Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MONO-LINYAH and DEMULEN 1/50-28 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MONO-LINYAH is: 10 mg orally once daily. The standard adult dose of DEMULEN 1/50-28 is: One tablet orally once daily for 28 consecutive days per cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MONO-LINYAH and DEMULEN 1/50-28 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MONO-LINYAH is classified as Category C. Pregnancy Category X. First trimester: High risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: Risk of oligohydr. DEMULEN 1/50-28 is classified as Category C. Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.